Actualités Daiichi Sankyo Co Ltd (PK) - DSKYF | Actions OTCMarkets

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATSEUBATS Europe
CHIXChi-X Europe
EUEuronext

	Prix en temps réel	Carnet d'ordres
BATSEUBATS Europe
CHIXChi-X Europe
EUEuronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Daiichi Sankyo Co Ltd (PK) (DSKYF)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

DSKYF Actualités

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

Patients with Hypertension at Risk Due to Physician Inertia

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Daiichi Sankyo Co Ltd (PK) (DSKYF) Actualités

Daiichi Sankyo Co Ltd (PK) (DSKYF)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

DSKYF Actualités

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

Patients with Hypertension at Risk Due to Physician Inertia

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres